000			03728nam a22003735i 4500
001			80557
003			ES-MaUEC
005			20230207040310.0
007			cr nn 008mamaa
008			140215s2014 gw | s |||| 0|eng d
020			_a9783642451959
024	7		_a10.1007/978-3-642-45195-9 _2doi
050		4	_aRC280.P7 _bP767 2014
245	1	0	_aProstate Cancer Prevention _cedited by Jack Cuzick, Mangesh A. Thorat.
260			_aBerlin, Heidelberg _bSpringer _c2014
300			_a1 recurso en línea (VIII, 169 páginas) _b11 ilustraciones, 4 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aRecent Results in Cancer Research _x0080-0015 _v202
505	0		_aBiology and natural history of prostate cancer -- Nutrition and prostate cancer -- Prostate cancer chemoprevention -- Lifestyle and dietary factors -- GWAS in prostate cancer predisposition and application to screening and prevention -- Risk prediction biomarkers â€ÃP -- Risk prediction biomarkers - TMPRSS2-ERG -- Risk prediction biomarkers â€ЃA3 -- Risk adapted chemoprevention for PCa -- Outlook for 5α reductase inhibitors in prostate cancer prevention -- Prostate cancer chemoprevention: Aspirin -- Prostate cancer chemoprevention: DFMO -- Prostate cancer chemoprevention: Lycopene -- Distinguishing aggressive from indolent prostate cancer -- Prognosis and Management of low grade disease - Management of Gleason 6 -- Prostate cancer prevention: Policy & Research implications.
520	3		_aProstate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals, and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely. Â{u0060}wide range of topics are covered by leading authorities in the field. The biology and natural history of prostate cancer are reviewed, and the role of lifestyle and dietary factors, assessed. Detailed attention is paid to risk prediction biomarkers and to the role of novel high-throughput nucleic acid-based technologies in improving risk prediction and thereby allowing tailored approaches to cancer prevention. Potential means of chemoprevention of prostate cancer are also reviewed in depth, covering the very positive new data on the impact of aspirin as well as evidence regarding 5α-reductase inhibitors, DFMO, and lycopene. Guidance is provided on the differentiation of aggressive from indolent disease, and the policy and research implications of recent findings are examined. This book will be of interest to both clinicians and researchers.
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
988			_aEBOOK, asignarmaterias, EBSPRINGER,
650		7	_aUrología _0 _2embne _9138565
650	2	7	_aUrología _0 _2embne _9138565
700	1		_aCuzick, Jack _eeditor literario _988849 _0Local
700	1		_aThorat, Mangesh A _eeditor literario _988850 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-642-45195-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12883104 _b10-10-17 _c11-11-15
998			_am _a_alco _a_vill _b11-11-15 _cm _dz _e- _feng _ggw _h0
945			_aRC280.P7 P767 2014 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11562924 _z06-04-17
999			_c80557 _d80557 _x1